- Report
- August 2023
- 225 Pages
Global
From €5754EUR$5,950USD£4,873GBP
- Report
- June 2023
- 175 Pages
Global
From €5754EUR$5,950USD£4,873GBP
- Report
- November 2023
- 30 Pages
Global
From €3143EUR$3,250USD£2,662GBP
- Report
- February 2024
- 110 Pages
Global
From €4352EUR$4,500USD£3,685GBP
- Report
- September 2023
- 150 Pages
Africa
From €5754EUR$5,950USD£4,873GBP
- Report
- September 2022
- 330 Pages
Global
From €4641EUR$4,799USD£3,930GBP
- Report
- October 2018
- 238 Pages
Global
From €3384EUR$3,499USD£2,866GBP
- Report
- June 2019
- 248 Pages
Global
From €1330EUR$1,375USD£1,126GBP
€2659EUR$2,750USD£2,252GBP
Advanced Therapy Medicinal Products (ATMPs) are a class of pharmaceuticals that are used to treat serious or life-threatening diseases and conditions. They are based on gene therapy, somatic cell therapy, and tissue engineering, and are designed to modify or replace a patient's cells or tissues. ATMPs are highly complex and require specialized manufacturing processes, and are subject to stringent regulatory requirements.
ATMPs are used to treat a wide range of diseases, including cancer, genetic disorders, and degenerative diseases. They are also used to treat conditions such as organ failure, autoimmune diseases, and cardiovascular diseases. ATMPs are often used in combination with other treatments, such as chemotherapy or radiation therapy.
Some companies in the ATMP market include Novartis, Gilead Sciences, Celgene, and Regeneron Pharmaceuticals. Show Less Read more